23:07 , Aug 15, 2019 |  BC Innovations  |  Product Development

Adaptive is surfing a wave of enthusiasm in disease detection, betting on the immune system

Adaptive’s float to more than $5 billion after its June IPO is largely based on its ambition to compete with the likes of Grail and Guardant in early diagnosis of cancer and other diseases by...
23:59 , Aug 14, 2019 |  BC Extra  |  Company News

Aug. 14 Company Quick Takes: Myriad plunges on sales concerns; plus AbbVie-Allergan, TB Alliance, Akari, Carmine

Myriad falls on sales forecast, GeneSight concerns  Myriad Genetics Inc. (NASDAQ:MYGN) tumbled $19.05 (43%) to $25.50 Wednesday, the day after the molecular diagnostics maker reported 4Q revenues of $215 million, below FactSet’s consensus of $222...
20:31 , Aug 9, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least four profitable biotechs and pharmas are slated to report earnings this week. (A) After market close in Europe, during market hours on U.S. exchanges Company Date Pre/post mkt 2Q19 EPS...
22:07 , Aug 1, 2019 |  BC Extra  |  Company News

With GeneSight health economics data in hand, Myriad wins UnitedHealth coverage

Myriad Genetics jumped $15.87 (55%) to $45.01 Thursday, lifting its market cap by $1.2 billion to $3.3 billion, after UnitedHealth said it will begin covering its genetic depression test. The decision, which goes into effect...
21:40 , Jul 11, 2019 |  BC Innovations  |  Distillery Therapeutics

Treating asthma, allergic diseases with mAbs against crystallized proteins

DISEASE CATEGORY: Inflammation INDICATION: Asthma argenx and VIB have developed antibodies against LGALS10 that could help treat asthma and other allergic airway diseases. Patients with severe asthma had crystals comprising LGALS10 in airway tissue and...
22:19 , Jun 19, 2019 |  BC Extra  |  Company News

June 19 Company Quick Takes: Catalent takes over manufacturing site from BMS; plus Lynparza, Myriad, Amgen and more

Catalent buys Italian facility from BMS  Catalent Inc. (NYSE:CTLT) will buy an Italian manufacturing facility from Bristol-Myers Squibb Co. (NYSE:BMY) for an undisclosed amount. Catalent will manufacture oral solid, biologics and sterile products at the...
02:03 , Jun 15, 2019 |  BioCentury  |  Politics, Policy & Law

Signs of hope on patent eligibility reform as Congress weighs arguments

The wait is still far from over for fixing the rules on what can be patented -- a move that could give diagnostics a fighting chance of becoming commercially viable. That said, a three-day Congressional...
21:53 , Jun 11, 2019 |  BC Innovations  |  Distillery Therapeutics

PSEN1 inhibition could treat T cell ALL

DISEASE CATEGORY: Cancer INDICATION: Acute lymphoblastic leukemia (ALL) Cell culture and mouse studies suggest inhibiting PSEN1 could help treat T cell ALL. In two human T cell ALL cell lines, a tool compound PSEN1 inhibitor...
01:39 , May 4, 2019 |  BioCentury  |  Product Development

Amyloid: how did we get here and what can we learn?

Unlike any other theory in drug development, the amyloid hypothesis of Alzheimer’s disease has maintained an almost cult-like following, despite two decades littered with a long line of late-stage failures and not a single success....
19:48 , May 3, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 22 profitable biotechs and pharmas are slated to report earnings this week. (A) During trading hours in Europe; premarket on U.S. exchange; (B) Fiscal 4Q; Company Date Pre/post mkt 1Q19...